专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

US20110201798A1 THERAPEUTIC COMPOSITIONS 有权
标题翻译：治疗组合物
公开(公告)号：US20110201798A1
公开(公告)日：2011-08-18
申请号：US12838230
申请日：2010-07-16
申请人： Muthiah MANOHARAN
发明人： Muthiah MANOHARAN
IPC分类号： C07H21/04
CPC分类号： C12N15/113 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0362 , A61K31/713 , A61K47/48123 , C07H21/02 , C07K14/775 , C12N15/111 , C12N15/1137 , C12N15/1138 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/344 , C12N2310/3515 , C12N2310/533 , C12N2320/32 , C12N2320/51 , C12N2320/53 , C12N2330/30
摘要： This application relates to therapeutic siRNA agents and methods of making and using the agents.
摘要翻译：本申请涉及治疗性siRNA剂及其制备和使用方法。

52. 发明授权

US6077714A Method for the preparation of free radical pharmaceuticals diagnostics and devices using selenium conjugates 失效
标题翻译：用于制备自由基药物诊断和使用硒共轭物的装置的方法
公开(公告)号：US6077714A
公开(公告)日：2000-06-20
申请号：US12156
申请日：1998-01-22
申请人： Julian E. Spallholz , Ted W. Reid
发明人： Julian E. Spallholz , Ted W. Reid
IPC分类号： A61K31/095 , A61K31/13 , A61K33/04 , A61K47/48 , H04M1/03 , H04M1/19 , G01N33/553
CPC分类号： A61K31/095 , A61K31/13 , A61K33/04 , A61K47/48023 , A61K47/48123 , A61K47/48992
摘要： The invention provides a method for making a selenium-carrier conjugate by covalently attaching (i) an organic selenium compound selected from the group consisting of RSeH, RSeR, RSeR', RSeSeR and RSeSeR', wherein R and R' are each an aliphatic residue containing at least one reactive group selected from the group consisting of aldehyde, amino, alcoholic, carboxylic, phosphate, sulfate, halogen or phenolic reactive groups and combinations thereof, to (ii) a carrier having a constituent capable of forming a covalent bond with said reactive groups of said selenium compound to produce a selenium-carrier conjugate which is capable of specific attachment to a target site. The carrier may be a protein, such as an antibody specific to a bacteria, virus, protozoa, or cell antigen, including without limitation, cell surface antigens, a peptide, carbohydrate, lipid, vitamin, drug, lectin, plasmid, liposome, nucleic acid or a non-metallic implantable device, such as an intraocular implant or a vascular shunt. The attachment of selenium compounds of the configurations described above to carriers when presented to either endogenous thiols, such as glutathione which occurs in all aerobic living cells, or exogenous thiols, such as glutathione or cysteine, produces superoxide (O.sub.2.sup..cndot.-), hydrogen peroxide, the hydroxyl radical (.cndot.OH) and other cytotoxic reactive oxygen species so as to collectively form a localized free radical pharmacology based upon the catalytic selenium anion, RSe.sup.-.
摘要翻译：本发明提供了通过共价连接（i）选自RSeH，RSeR，RSeR'，RSeSeR和RSeSeR'的有机硒化合物来制备硒 - 载体缀合物的方法，其中R和R'各自为脂族残基含有至少一个选自醛，氨基，醇，羧酸，磷酸酯，硫酸酯，卤素或酚反应性基团的反应性基团及其组合，（ii）具有能与所述化合物形成共价键的成分的载体所述硒化合物的反应性基团产生能够特异性附着于靶位点的硒 - 载体缀合物。载体可以是蛋白质，例如细菌，病毒，原生动物或细胞抗原特异的抗体，包括但不限于细胞表面抗原，肽，碳水化合物，脂质，维生素，药物，凝集素，质粒，脂质体，核酸酸或非金属可植入装置，例如眼内植入物或血管分流装置。当呈现给所有需氧活细胞中发生的内源性硫醇，如谷胱甘肽或外源硫醇，如谷胱甘肽或半胱氨酸时，上述构型的硒化合物与载体的连接产生超氧化物（O2-），过氧化氢，羟基自由基（.OH）和其他细胞毒性活性氧，以便共同形成基于催化硒阴离子RSe-的局部自由基药理学。

53. 发明授权

US6001644A Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR 失效
标题翻译：包含脂质载体和编码CFTR的DNA的哺乳动物转化复合物
公开(公告)号：US6001644A
公开(公告)日：1999-12-14
申请号：US256004
申请日：1994-08-22
申请人： Robert J. Debs , Ning Zhu
发明人： Robert J. Debs , Ning Zhu
IPC分类号： C12N15/09 , A61K9/00 , A61K9/127 , A61K31/70 , A61K39/00 , A61K47/48 , A61K48/00 , C07K14/00 , C07K14/47 , C07K14/55 , C12N15/88 , C12N15/00 , C12N15/63
CPC分类号： A61K9/0078 , A61K47/48023 , A61K47/48046 , A61K47/48053 , A61K47/48076 , A61K47/48123 , A61K47/48815 , A61K48/00 , A61K9/1272 , C07K14/00 , C07K14/4712 , C07K14/55 , C12N15/88 , A01K2217/05 , A61K39/00
摘要： Compositions comprising lipid carrier-CFTR nucleic acid complexes are disclosed.
摘要翻译： PCT No.PCT / US92 / 11004 Sec。 371日期1994年8月22日 102（e）日期1994年8月22日PCT提交1992年12月17日PCT公布。出版物WO93 / 12240 PCT 日期：1993年6月24日公开了包含脂质载体-CFTR核酸复合物的组合物。

54. 发明授权

US5939401A Cationic amphiphile compositions for intracellular delivery of therapeutic molecules 失效
标题翻译：用于细胞内递送治疗分子的阳离子两亲物组合物
公开(公告)号：US5939401A
公开(公告)日：1999-08-17
申请号：US680354
申请日：1996-07-15
申请人： John Marshall , David J. Harris , Edward R. Lee , Craig S. Siegel , Simon J. Eastman , Chau-Dung Chang , Ronald K. Scheule , Seng H. Cheng
发明人： John Marshall , David J. Harris , Edward R. Lee , Craig S. Siegel , Simon J. Eastman , Chau-Dung Chang , Ronald K. Scheule , Seng H. Cheng
IPC分类号： A61K47/48 , A61K9/127 , A61K31/70 , A61K47/28 , A61K48/00 , C07J41/00 , C07J43/00 , C12N15/87 , C12N15/88 , A61K38/00 , C07J9/00
CPC分类号： A61K9/1272 , A61K47/48038 , A61K47/48046 , A61K47/48123 , C07J41/0005 , C07J41/0055 , C07J41/0061 , C07J43/003 , C12N15/88 , A61K48/00
摘要： Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. By this invention, such cationic amphiphile is used in a state in which it is capable of accepting additional protons, i.e., it is not fully protonated. For purposes of this invention, cationic amphiphiles may be considered to encompass four general categories: (A) T-shaped/steroid-based amphiphiles; (B) T-shaped/non steroid-based amphiphiles; (C) non T-shaped/steroid based amphiphiles and (D) non T-shaped/non steroid-based amphiphiles.
摘要翻译：提供了新的阳离子两亲物，其促进生物活性（治疗性）分子进入细胞。通过本发明，这种阳离子两亲物以其能够接受另外的质子即不完全质子化的状态使用。为了本发明的目的，阳离子两亲物可以被认为包括四个一般类别：（A）T型/类固醇基两亲物; （B）T型/非类固醇基两亲物; （C）非T型/类固醇基两亲物和（D）非T型/非类固醇基两亲物。

55. 发明授权

US5879917A Programmable genotoxic agents and uses therefor 失效
公开(公告)号：US5879917A
公开(公告)日：1999-03-09
申请号：US434664
申请日：1995-05-04
申请人： John M. Essigmann , Robert G. Croy , Kevin J. Yarema , Marshall Morningstar
发明人： John M. Essigmann , Robert G. Croy , Kevin J. Yarema , Marshall Morningstar
IPC分类号： A61K47/48 , C12N15/00 , C07J1/00
CPC分类号： A61K47/481 , A61K47/48023 , A61K47/48123 , A61K47/48146 , A61K47/48246
摘要： The compositions and methods disclosed herein provide heterobifunctional programmable genotoxic compounds that can be designed to kill selected cells present in a heterogenous cell population. The present compounds comprise a first agent that inflicts damage on cellular DNA, and a second agent that attracts a macromolecular cell component such as a protein, which in turn shields genomic lesions from repair. Unrepaired lesions therefore persist in the cellular genome and contribute to the death of selected cells. In contrast, lesions formed in nonselected cells, which lack the cell component, are unshielded and thus are repaired. As a result, compounds described herein are less toxic to nonselected cells. Compounds of this invention can be designed to cause the selective killing of transformed cells, viral-infected cells and the like.

56. 发明授权

US5858784A Expression of cloned genes in the lung by aerosol- and liposome-based delivery 失效
标题翻译：通过气溶胶和脂质体递送在克隆基因中表达克隆的基因
公开(公告)号：US5858784A
公开(公告)日：1999-01-12
申请号：US972135
申请日：1992-11-05
申请人： Robert James Debs , Ning Zhu
发明人： Robert James Debs , Ning Zhu
IPC分类号： A01K67/027 , A61K9/00 , A61K9/12 , A61K9/127 , A61K9/72 , A61K31/711 , A61K35/76 , A61K38/00 , A61K39/00 , A61K47/16 , A61K47/18 , A61K47/28 , A61K47/48 , A61K48/00 , A61P1/00 , A61P11/00 , A61P11/06 , A61P31/04 , A61P35/00 , C07K14/47 , C12N5/10 , C12N15/09 , C12N15/88 , C12P21/02 , C12R1/91 , C12N15/87
CPC分类号： A61K9/0078 , A61K47/48023 , A61K47/48046 , A61K47/48076 , A61K47/48123 , A61K47/48815 , A61K48/00 , A61K9/1272 , C07K14/4712 , C12N15/88 , A01K2217/05 , A61K39/00
摘要： Methods and compositions for producing a mammal capable of expressing an exogenously supplied gene in cells of the airway are disclaimed. Liposome-nucleic acid complexes are prepared then delivered via aerosol to the lung airway. The invention provides a direct method for transforming pulmonary cells as a means for treating disorders of the lung as for providing a means for delivering substances systematically following expression in the lung.
摘要翻译：放弃能够在气道细胞中表达外源供应基因的哺乳动物的方法和组合物。制备脂质体 - 核酸复合物，然后通过气溶胶递送至肺气道。本发明提供了用于转化肺细胞作为治疗肺疾病的手段的直接方法，以提供在肺中表达后系统递送物质的方法。

57. 发明授权

US5811406A Dry powder formulations of polynucleotide complexes 失效
标题翻译：干粉配方的多核苷酸复合物
公开(公告)号：US5811406A
公开(公告)日：1998-09-22
申请号：US482254
申请日：1995-06-09
申请人： Francis C. Szoka, Jr. , Alain Rolland , Jinkang Wang
发明人： Francis C. Szoka, Jr. , Alain Rolland , Jinkang Wang
IPC分类号： C12N15/09 , A61K9/00 , A61K9/127 , A61K31/70 , A61K47/22 , A61K47/26 , A61K47/48 , A61K48/00 , A61P11/00 , C12N15/10 , C12N15/63 , C12N15/88
CPC分类号： A61K9/0075 , A61K31/7105 , A61K31/711 , A61K31/713 , A61K47/26 , A61K47/48046 , A61K47/48053 , A61K47/48123 , A61K47/48815 , A61K47/48884 , A61K48/00 , A61K9/1272 , C12N15/88
摘要： Polynucleotide complexes are stabilized by adding a cryoprotectant compound and lyophilizing the resulting formulation. The lyophilized formulations are milled or sieved into a dry powder formulation which may be used to deliver the polynucleotide complex. Delivery of the polynucleotide to a desired cell tissue is accomplished by contacting the tissue with the powder to rehydrate it. In a preferred embodiment, a dry powder formulation is used to transfer genetic information to the cells of the respiratory tract.
摘要翻译：通过加入冷冻保护剂化合物并冻干所得制剂来稳定多核苷酸复合物。将冻干制剂研磨或筛分成可用于递送多核苷酸复合物的干粉制剂。将多核苷酸递送至所需的细胞组织通过使组织与粉末接触以使其再水合来实现。在优选的实施方案中，使用干粉制剂将遗传信息转移到呼吸道细胞。

58. 发明授权

US5767099A Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules 失效
标题翻译：含有氨基酸或衍生化氨基酸基团的阳离子两亲物用于治疗分子的细胞内递送
公开(公告)号：US5767099A
公开(公告)日：1998-06-16
申请号：US546086
申请日：1995-10-20
申请人： David J. Harris , Edward R. Lee , Craig S. Siegel , Eric A. Rowe , Shirley C. Hubbard
发明人： David J. Harris , Edward R. Lee , Craig S. Siegel , Eric A. Rowe , Shirley C. Hubbard
IPC分类号： A61K9/127 , A61K47/48 , A61K48/00 , C07J41/00 , C07J43/00 , C12N15/88 , A61K31/70 , A61K31/56 , B61F17/28 , A61K17/28
CPC分类号： A61K9/1272 , A61K47/48023 , A61K47/48038 , A61K47/48046 , A61K47/48123 , A61K48/00 , C07J41/0005 , C07J41/0055 , C07J41/0061 , C07J43/003 , C12N15/88 , Y10S516/07 , Y10S516/915
摘要： Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile. Novel and highly effective plasmid constructs are also disclosed, including those that are particularly effective at providing gene therapy for clinical conditions complicated by inflammation. Additionally, targeting of organs for gene therapy by intravenous administration of therapeutic compositions is described.
摘要翻译：提供了新的阳离子两亲物，其促进生物活性（治疗性）分子进入细胞。两亲物含有衍生自类固醇的单亲或二烷基胺或烷基或酰基的亲脂基团; 和在生理pH下可质子化的阳离子基团，衍生自胺，烷基胺或多烷基胺。还提供了通常通过使一种或多种阳离子两亲物的分散体与治疗分子接触而制备的治疗组合物。根据本发明的实践可以递送到细胞中的治疗分子包括DNA，RNA和多肽。本发明治疗组合物的代表性用途包括提供基因治疗以及向细胞递送反义多核苷酸或生物活性多肽。关于基因治疗的治疗组合物，通常以与阳离子两亲物络合的质粒的形式提供DNA。还公开了新型和高效的质粒构建体，包括在为炎症复杂的临床病症提供基因治疗方面特别有效的质粒构建体。另外，描述了通过静脉内施用治疗组合物靶向用于基因治疗的器官。

59. 发明授权

US5756353A Expression of cloned genes in the lung by aerosol-and liposome-based delivery 失效
标题翻译：通过气溶胶和脂质体递送在克隆基因中表达克隆的基因
公开(公告)号：US5756353A
公开(公告)日：1998-05-26
申请号：US487793
申请日：1995-06-07
申请人： Robert J. Debs
发明人： Robert J. Debs
IPC分类号： A61K9/00 , A61K9/12 , A61K9/127 , A61K39/00 , A61K47/48 , A61K48/00 , C07K14/47 , C12N15/88 , C12N15/87 , A61K49/00
CPC分类号： A61K9/0078 , A61K47/48046 , A61K47/48076 , A61K47/48123 , A61K47/48815 , A61K48/00 , A61K9/1272 , C07K14/4712 , C12N15/88 , A01K2217/05 , A61K39/00
摘要： Methods for the delivery of genes directly to the lungs are disclosed. Liposome-nucleic acid complexes are delivered via aerosol with the subsequent in viva expression of a protein encoded by the delivered gene. The invention provides a convenient method for treating pulmonary disorders, as well as for delivering substances systemically via the lung.
摘要翻译：公开了将基因直接递送到肺的方法。脂质体 - 核酸复合物通过气溶胶递送，随后用输送的基因编码的蛋白质进行表达。本发明提供了治疗肺部疾病以及通过肺部全身递送物质的方便方法。

60. 发明授权

US5753262A Cationic lipid acid salt of 3beta�N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof 失效
标题翻译： 3β[N-（N'，N'-二甲基氨基乙烷） - 氨基甲酰基]胆甾醇及其无卤无溶剂的前脂质体冻干物的阳离子脂质酸盐
公开(公告)号：US5753262A
公开(公告)日：1998-05-19
申请号：US485866
申请日：1995-06-07
申请人： Joseph W. Wyse , Charles D. Warner
发明人： Joseph W. Wyse , Charles D. Warner
IPC分类号： A61K9/127 , A61K9/133 , A61K48/00 , C07J41/00 , C12N15/88 , C07J9/00 , C12N15/64 , G01N33/92
CPC分类号： A61K47/48123 , A61K48/00 , A61K9/1272 , C07J41/0055 , C12N15/88
摘要： This invention discloses a novel cationic lipid acid salt of 3.beta.�N-(N',N'-dimethylaminoethane)-carbamoyl!cholesterol. This invention further discloses a transmembrane compatible body suitable for transfection of animals and animal cells with nucleotides such as DNA, RNA, and synthetic nucleotides. Such transmembrane compatible bodies arise from hydratable non-liposomal halogenated solvent-free lyophilate comprising 3.beta.�N-(N',N'-dimethylaminoethane)-carbamoyl!cholesterol and DOPE. This invention yet further discloses a halogenated solvent-free aqueous solution, suitable for lyophilization into a preliposomal powder, wherein the solution comprises 3.beta.�N-(N',N'-dimethylaminoethane)-carbamoyl!cholesterol wherein substantially all 3.beta.�N-(N',N'-dimethylaminoethane)-carbamoyl!cholesterol is dissolved.
摘要翻译：本发明公开了3β[N-（N'，N'-二甲基氨基乙烷） - 氨基甲酰]胆固醇的新型阳离子脂质酸盐。本发明进一步公开了一种适于用DNA，RNA和合成核苷酸等核苷酸转染动物细胞的跨膜相容体。这种跨膜相容体由含有3β[N-（N'，N'-二甲基氨基乙烷） - 氨基甲酰]胆固醇和DOPE的可水合非脂质体无卤素无溶剂的冻干物产生。本发明进一步公开了一种适用于冻干成前脂质体粉末的无卤素溶剂的水溶液，其中该溶液包含3β[N-（N'，N'-二甲基氨基乙烷） - 氨基甲酰基]胆固醇，其中基本上全部为3β[N - （N'，N'-二甲基氨基乙烷） - 氨基甲酰基]胆固醇溶解。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式